Dados do Trabalho

Título

Aducanumab as a new therapeutic possibility for Alzheimer's disease

Resumo

Introduction: Alzheimer's disease (AD) corresponds to a cognitive and functional decline associated with age, specific neuropathology and in its earliest stages it can be characterized by a deficit in the ability to encode and store memories. DA is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by neurodegeneration. Regarding therapeutic options, there is still a relevant search for improvements in the treatment of this disease, and for that, the path that leads to the use of anti-amyloid agents showed significant efficacy in clinical trials. Agents with potential for short-term approval meet these criteria: the injectable antibodies, aducanumab, gantenerumab, and BAN 2401, and an oral small-molecule agent, ALZ-801. Objective: To analyze the new therapeutic possibilities in the treatment of Alzheimer's Disease and to understand the relevance of this new therapy for patients affected by this disease. Methodology: This is a systematic literature review based on data extraction in indexes such as PUBMED and MEDLINE. Publications from 2018 to 2022 were considered, in English and with the following descriptors: Aducanumab. Alzheimer's. Neurology. Results: Alzheimer's disease currently ranks as the most common form of neurodegenerative disease, and its symptomatic treatment is able to offer only a modest and measurable effect on cognition. Regarding the aforementioned anti-amyloid agents, Aducanumab showed significant efficacy in clinical and biomarker results. O aducanumab atua ligando-se e reduzindo o Aβ solúvel e insolúvel de maneira dependente da dose e com cerca de um ano de infusões intravenosas mensais de aducanumab foi capaz de reduzir a Aβ cerebral, o que resulta em uma desaceleração do declínio clínico medido. Conclusion: In this way, it is noticed that new possibilities for the treatment of AD appear on the horizon and create new hopes to guarantee a better quality of life and who knows even evolve to a clinical decline of this pathology. Evidently, there is still a long way to go, mainly due to the complexity of the pathophysiological factors of this comorbidity, but the possibility of an effective treatment opens up new hopes.